ZIANA Drug Patent Profile

When do Ziana patents expire, and what generic alternatives are available?

Ziana is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ZIANA is clindamycin phosphate; tretinoin. There are fifty-five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the clindamycin phosphate; tretinoin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ziana

A generic version of ZIANA was approved as clindamycin phosphate; tretinoin by ACTAVIS MID ATLANTIC on June 12^th, 2015.

Summary for ZIANA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	23
Drug Prices:	Drug price information for ZIANA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZIANA
What excipients (inactive ingredients) are in ZIANA?	ZIANA excipients list
DailyMed Link:	ZIANA at DailyMed

See drug prices for ZIANA

Pharmacology for ZIANA

Drug Class	Lincosamide Antibacterial Retinoid
Physiological Effect	Decreased Sebaceous Gland Activity Neuromuscular Blockade

Paragraph IV (Patent) Challenges for ZIANA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZIANA	Gel	clindamycin phosphate; tretinoin	1.2%/0.025%	050802	1	2010-12-17

US Patents and Regulatory Information for ZIANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006	AB1	RX	Yes	Yes

Expired US Patents for ZIANA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006
Bausch	ZIANA	clindamycin phosphate; tretinoin	GEL;TOPICAL	050802-001	Nov 7, 2006

International Patents for ZIANA

See the table below for patents covering ZIANA around the world.

Country	Patent Number	Title	Estimated Expiration
Canada	2063576	VEHICULES A LIBERATION LENTE SERVANT A REDUIRE AU MINIMUM L'IRRITATION CUTANEE DUE A DES COMPOSITIONS TOPIQUES (SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS)
Germany	69029804
European Patent Office	0481007	VEHICULES A LIBERATION LENTE REDUISANT AU MINIMUM L'IRRITATION DERMIQUE DUE A DES COMPOSITIONS A USAGE LOCAL contenant des rétinoides (SLOW RELEASE VEHICLES FOR MINIMIZING SKIN IRRITANCY OF TOPICAL COMPOSITIONS containing retinoids)
World Intellectual Property Organization (WIPO)	9014833
Argentina	030093	SISTEMA PARA LA DISTRIBUCION TOPICA DEL GEL
Austria	429922

Supplementary Protection Certificates for ZIANA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	PA2013025	Lithuania		PRODUCT NAME: CLINFAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992	1390049-3	Sweden		PRODUCT NAME: KLINDAMYCIN (SOM KLINDAMYCINFOSFAT) OCH TRETINOIN; NAT. REG. NO/DATE: MTNR 46193 20130503; FIRST REG.: IR PA1332/043/001 20130322
1304992	92401	Luxembourg		PRODUCT NAME: CLINDAMYCINE(EN TANT QUE PHOPSHATE DE CLINDAMYCINE)ET TRETINOINE
1304992	CR 2013 00053	Denmark		PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992	PA2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323

Market Dynamics and Financial Trajectory for Ziana (Clindamycin Phosphate and Tretinoin)

Last updated: January 11, 2026

Summary

Ziana®, a topical combination therapy comprising clindamycin phosphate and tretinoin, is indicated primarily for the treatment of acne vulgaris. Since its FDA approval in 2000, Ziana has maintained a significant position within the acne therapeutics market. This report delineates the current market landscape, key financial factors, competitive positioning, and future growth prospects for Ziana, analyzing the dynamic influences shaping its trajectory. It also presents comparative data against competing agents and explores the regulatory, clinical, and commercial factors impacting its performance.

---

What Are the Core Components and Indications of Ziana?

Ingredient	Therapeutic Class	Indication	Dosage Forms	Approved Since
Clindamycin phosphate	Antibiotic, lincosamide	Acne vulgaris	Topical gel (1%)	2000 (FDA)
Tretinoin	Retinoid	Acne vulgaris	Topical gel, cream	1971 (FDA approval for tretinoin)

Ziana combines an antibiotic with a retinoid to target multiple pathways in acne etiology, including Propionibacterium acnes inhibition and keratinocyte normalization.

---

Market Dynamics Driving Ziana's Growth

1. Market Size and Segment Analysis

• The global acne treatment market was valued at approximately $4.2 billion in 2022 (SOURCE: Grand View Research)[1], with topical therapies comprising over 65% of the market.
• The North American region holds roughly 40% of global dermatological sales, driven by high prescription rates and greater awareness.
• The segment for combination therapies like Ziana is expanding, owing to increasing resistance to monotherapies and consumer demand for multi-mechanism approaches.

2. Key Drivers

• Recurrent and Moderate Acne Prevalence: Over 85 million Americans suffer from acne, representing a persistent demand (SOURCE: American Academy of Dermatology Association)[2].

• Efficacy and Safety Profile: Ziana’s proven efficacy in reducing inflammatory lesions, with a tolerable side effect profile, sustains its prescription rates.

• Guidelines and Clinical Endorsements: The 2016 American Academy of Dermatology guidelines recommend combination therapy for moderate-to-severe cases, bolstering Ziana’s position.

• Rising Prescription Trends: According to IQVIA data, prescriptions for topical retinoids and antibiotics rose by approximately 4% annually over the last five years[3].

3. Competitive Landscape

Competitors	Key Features	Market Share (Estimated 2022)	Notable Products
Differin (adapalene)	Retinoid-only	25%	Differin Gel
Epiduo (adapalene + benzoyl peroxide)	Combination	20%	Epiduo Gel
Duac (clindamycin + benzoyl peroxide)	Antibiotic combo	15%	Duac Gel
Others	Various	20%	various generics and branded products

Ziana holds an estimated 15-20% of the topical acne market.

4. Pricing and Reimbursement

• Retail price ranges between $250-$350 for a 45g tube (SOURCE: GoodRx)[4].
• Insurance coverage is broad; however, copays and formulary placements influence prescribing patterns.
• The generic landscape is sparse, protecting Ziana’s premium positioning somewhat.

5. Regulatory and Policy Environment

• The FDA’s Risk Evaluation and Mitigation Strategies (REMS) related to antibiotic stewardship moderately influence prescribers’ preferences.
• Increasing emphasis on antimicrobial resistance (AMR) management could pressure the use of antibiotics like clindamycin, potentially impacting Ziana’s market share.

---

Financial Trajectory: Revenue, Profitability, and Forecasts

1. Historical Revenue Performance

Year	Estimated Global Revenue	Growth Rate	Key Drivers
2018	$150 million	2%	Stable prescribing
2019	$155 million	3.3%	Market expansion
2020	$160 million	3.2%	Pandemic-driven teledermatology
2021	$165 million	3.1%	Increased adherence initiatives
2022	$170 million	3%	Competitive pressures

Note: Revenue estimates are derived from industry reports, as actual sales data are proprietary.

2. Cost Structure and Profit Margins

• Manufacturing Costs: Estimated at $30-$50 per tube.
• Distribution and Marketing: approximately 20% of revenue.
• Net Profit Margin: Typically 25-30% due to brand dominance and high pricing.

3. Forecasting Future Growth

Projection Period	CAGR	Predicted Revenue	Assumptions
2023-2027	3-4%	$185-$210 million	Steady prescription growth, moderate competition
2028-2030	2-3%	$210-$225 million	Market saturation, potential biosimilar entry

Potential drivers include new formulations, expanded indications, and strategic marketing.

4. Risks and Opportunities

Risks	Opportunities
Rising antimicrobial resistance policies	Launch of generic versions or biosimilars
Competition from non-antibiotic topical agents	Expansion into adolescent demographics
Regulatory focus on antibiotic stewardship	Development of fixed-dose combinations with improved profiles

---

What Are the Key Market Challenges and Opportunities?

Challenges

• Antimicrobial stewardship policies may limit antibiotic prescriptions.
• Emergence of biosimilars and generics could erode margins.
• Adherence issues due to local skin irritation can impact effectiveness and usage.

Opportunities

• Expansion into new markets, especially Asia-Pacific and Europe.
• Formulation innovations, such as lower-irritant gels.
• Combination strategies for resistant acne strains.
• Digital marketing and teledermatology collaborations to increase penetration.

---

How Does Ziana Compare to Major Competitors?

Feature	Ziana	Differin	Epiduo	Duac
Active Ingredients	Clindamycin + Tretinoin	Adapalene	Adapalene + Benzoyl Peroxide	Clindamycin + Benzoyl Peroxide
Market Position	Premium, branded	Over-the-counter, first-line	Prescription, moderate	Prescription, antibiotic class
Strengths	Efficacy for inflammatory acne	OTC accessibility	Efficacy, less irritation	Strong activity against bacteria
Weaknesses	Antibiotic resistance concerns	Less effective for resistant acne	Lack of antibiotic component	Antibiotic stewardship issues

---

Key Factors Influencing Ziana’s Future Market Trajectory

Factor	Impact	Strategy Considerations
Antibiotic Stewardship	Potential prescription restrictions	Emphasize adherence to guidelines, develop non-antibiotic combinations
Market Expansion	Higher revenue potential	Penetrate emerging markets with tailored marketing
Clinical Trials	Strengthen efficacy profile	Invest in studies for resistant acne and new indications
Regulatory Trends	Influence prescribing policies	Engage with policymakers for balanced approaches

---

Key Takeaways

• Stable Market Position: Ziana maintains a significant share of the adult and adolescent acne market, buoyed by its proven efficacy and brand recognition.
• Revenue Growth: Projected modest CAGR of 3-4% through 2027, driven by prescription volume increases and market expansion.
• Competitive Factors: Rising concerns around antibiotic resistance and the advent of non-antibiotic therapies could challenge Ziana's dominance.
• Innovation Aspects: Opportunities exist in formulation improvements and expanding indications to reinforce market relevance.
• Regulatory Environment: Policies favoring antibiotic stewardship may necessitate strategic adaptation and diversification.

---

Five Frequently Asked Questions (FAQs)

1. How does the growing concern over antibiotic resistance impact Ziana’s future sales?

Antibiotic resistance initiatives may restrict prescriptions of topical antibiotics like clindamycin, potentially reducing Ziana’s market share. However, alliances with stewardship programs and development of non-antibiotic formulations could offset this impact.

2. Are there any generic equivalents for Ziana?

Currently, the proprietary status and combination nature of Ziana limit generic competition. However, generic formulations of its individual components (clindamycin, tretinoin) are available and may be substituted for Ziana in certain markets.

3. What growth opportunities exist beyond the current indications?

Potential avenues include expanding into pediatric populations, managing resistant acne, and developing fixed-dose combinations that minimize irritation and enhance compliance.

4. How may new formulations influence Ziana’s market share?

Innovative formulations with improved tolerability or convenience can boost adherence and expand clinical utility, thereby strengthening Ziana’s market presence.

5. What strategic actions should manufacturers consider to sustain Ziana’s profitability?

Investing in clinical research, engaging in targeted marketing, exploring licensing deals in emerging markets, and diversifying into related dermatologic indications are critical strategies for maintaining profitability.

---

References

1. Grand View Research. Acne Treatment Market Size & Trends, 2022.
2. American Academy of Dermatology Association. Acne Prevalence Data, 2022.
3. IQVIA. Prescription Trends in Dermatology, 2022.
4. GoodRx. Acne Medication Pricing Data, 2023.

---

By understanding these dynamics, stakeholders can make informed decisions about investments, strategic partnerships, and competitive positioning related to Ziana in the evolving dermatology landscape.